2018
Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study
Oldham MA, Hawkins KA, Lin IH, Deng Y, Hao Q, Scoutt LM, Yuh DD, Lee HB. Depression Predicts Delirium After Coronary Artery Bypass Graft Surgery Independent of Cognitive Impairment and Cerebrovascular Disease: An Analysis of the Neuropsychiatric Outcomes After Heart Surgery Study. American Journal Of Geriatric Psychiatry 2018, 27: 476-486. PMID: 30709616, PMCID: PMC6443412, DOI: 10.1016/j.jagp.2018.12.025.Peer-Reviewed Original ResearchConceptsMiddle cerebral arteryMild cognitive impairmentCerebrovascular diseaseCognitive impairmentRisk factorsCoronary artery bypass graft surgeryStenosis severityProspective observational cohort studyArtery bypass graft surgeryBilateral middle cerebral arteriesTertiary care academic hospitalHeart Surgery studyPreoperative cognitive assessmentUndergoing CABG surgeryBypass graft surgeryConfusion Assessment MethodRisk of deliriumDelirium risk factorsObservational cohort studyPostoperative day 2Clinical Dementia RatingDepression InterviewPreoperative depressionStructured HamiltonStudy psychiatristCognition among individuals along a spectrum of increased risk for Parkinson’s disease
Chahine LM, Urbe L, Caspell-Garcia C, Aarsland D, Alcalay R, Barone P, Burn D, Espay AJ, Hamilton JL, Hawkins KA, Lasch S, Leverenz JB, Litvan I, Richard I, Siderowf A, Coffey CS, Simuni T, Weintraub D, Initiative T. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLOS ONE 2018, 13: e0201964. PMID: 30125297, PMCID: PMC6101368, DOI: 10.1371/journal.pone.0201964.Peer-Reviewed Original ResearchConceptsParkinson's diseaseIdiopathic REM sleep behavior disorderParkinson's Progression Markers Initiative (PPMI) studyDe novo Parkinson's diseaseREM sleep behavior disorderDopamine transporterNon-motor symptomsNovo Parkinson's diseaseSleep behavior disorderNon-motor featuresSymbol Digit Modalities TestBaseline neuropsychological performanceMontreal Cognitive AssessmentFuture neurodegenerationLewy bodiesInclusion criteriaSpectrum of riskMutation carriersInitiative studyCohortBehavior disorderCognitive functionCognitive test scoresModalities TestNeuropsychological performance
2012
Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study
Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, Stern MB, Marek K, Investigators T. Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study. Movement Disorders 2012, 27: 406-412. PMID: 22237833, PMCID: PMC6342466, DOI: 10.1002/mds.24892.Peer-Reviewed Original ResearchConceptsNonmotor featuresProdromal featuresOlfactory testingRapid eye movement sleep behaviour disorder symptomsSyndrome StudyPennsylvania Smell Identification TestDopamine transporter imagingPercent of subjectsSmell Identification TestRisk of PDFuture neurodegenerationHyposmic subjectsOlfactory dysfunctionImpaired olfactionTransporter imagingMotor functionMotor featuresSmell testNeurological diagnosisUndiagnosed individualsHyposmiaScreening testSpecific markersDisorder symptomsFurther assessment
2011
Age and Gender but Not Common Chronic Illnesses Predict Odor Identification in Older African Americans
Hawkins KA, Pearlson GD. Age and Gender but Not Common Chronic Illnesses Predict Odor Identification in Older African Americans. American Journal Of Geriatric Psychiatry 2011, 19: 777-782. PMID: 21873833, DOI: 10.1097/jgp.0b013e3181f7d8e1.Peer-Reviewed Original ResearchConceptsBrief Smell Identification TestOlder African AmericansChronic illnessBSIT scoresHealthy older African AmericansCommon chronic illnessCommon chronic conditionsLoss of smellSmell Identification TestAfrican AmericansSpecific neurodegenerative diseasesThyroid disordersChronic conditionsLimited normative dataClinical utilityOlder subjectsAge 55Odor identificationNeurodegenerative diseasesGeneral communityEarly detectionMinority cohortGlobal cognitionDemographic predictorsIdentification Test
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosisIncidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2008
Self-Reported Distress After Cognitive Testing in Patients With Alzheimer's Disease
Lai JM, Hawkins KA, Gross CP, Karlawish JH. Self-Reported Distress After Cognitive Testing in Patients With Alzheimer's Disease. The Journals Of Gerontology Series A 2008, 63: 855-859. PMID: 18772474, PMCID: PMC2733161, DOI: 10.1093/gerona/63.8.855.Peer-Reviewed Original ResearchConceptsSelf-reported distressCognitive testingDepressive symptomsDisease experienceSpecific patient factorsModerate AD patientsMultivariate logistic regressionCognitive performanceMore distressDemographic factorsTest performanceAlzheimer's disease (AD) experienceIntact patientsMultivariable analysisPatient factorsPatient awarenessAD patientsLevel of distressModerate ADPredictors of distressDementia severityPatientsAlzheimer's diseaseBivariate analysisLogistic regression
2007
Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population
Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, Breier A, Glist J, Addington J, Perkins DO, McGlashan TH. Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in a prodromal population. The British Journal Of Psychiatry 2007, 191: 355-356. PMID: 17906248, DOI: 10.1192/bjp.bp.106.031195.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersTime-dependent Cox regression analysisCox regression analysisMedication-free intervalOlanzapine treatmentPlacebo groupPharmacological treatmentProdromal symptomsRisk factorsProdromal populationSpeech illusionsDisordersRegression analysisYear 2TreatmentSignificant interactionYear 1Symptoms
2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patientsA Randomized Clinical Trial of a Manual-Guided Risk Reduction Intervention for HIV-Positive Injection Drug Users
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A Randomized Clinical Trial of a Manual-Guided Risk Reduction Intervention for HIV-Positive Injection Drug Users. Health Psychology 2003, 22: 223-228. PMID: 12683743, DOI: 10.1037/0278-6133.22.2.223.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV-positive injection drug usersHIV-seropositive injection drug usersHIV harm reduction programsRisk behaviorsHealth promotion behaviorsRisk reduction interventionsHarm reduction programsHigh-risk behaviorsAddiction severity scoresNational AIDS Demonstration Research projectAntiretroviral medicationsMethadone maintenanceSeverity scoreClinical trialsTreatment phasePromotion behaviorsReduction interventionsTreatment entryIllicit opiatesHarm reductionDemonstration research projectsPatientsReduction programs